Full-Time
Electrical Maintenance Technician
Posted on 8/20/2026
Dr. Reddy's Laboratories
10,001+ employees
Global generic medicines and APIs exporter
No salary listed
Mirfield, UK
In Person
 Electrical Engineering (1) |
|---|
Get referred to Dr. Reddy's Laboratories
See people who can refer or advise you
- NVQ Level 3, a recognised apprenticeship, or an equivalent qualification in Electrical Engineering, Instrumentation, or a related discipline.
- City & Guilds 18th Edition Wiring Regulations qualification.
- CompEx Ex01–Ex04 Gas and Ex05–Ex06 Dust qualifications.
- Experience working on industrial electrical systems, process instrumentation, and control systems.
- IPAF certification for MEWP operation.
- Working knowledge of permit-to-work systems, electrical isolation, and Lockout/Tagout requirements.
- Strong electrical and instrumentation fault-finding and problem-solving ability.
- Ability to interpret and update electrical schematics, P&IDs, loop drawings, and control system documentation.
- Familiarity with SAP CMMS or similar maintenance management systems.
- Calibration and instrumentation experience.
- Knowledge of PLCs, variable speed drives, and industrial control systems.
- Root cause analysis and structured problem-solving capability.
- Ability to support audits, inspections, and regulatory assessments.
- Ability to prioritise work safely and effectively in a live manufacturing environment.
- Carry out planned preventative maintenance and manage work orders in SAP CMMS.
- Respond to breakdowns, troubleshoot, and resolve electrical, control, and instrumentation faults.
- Maintain, troubleshoot, and repair electrical distribution systems, motor control centres, control panels, drives, and field devices.
- Inspect, test, and maintain electrical installations in line with statutory requirements and site procedures.
- Carry out calibration, verification, and maintenance of process instrumentation and critical site instruments.
- Support PLC, HMI, SCADA, and industrial control systems, including authorised fault diagnosis and minor modifications.
- Maintain and update electrical drawings, loop drawings, schematics, SOPs, manuals, calibration records, and equipment documentation.
- Work safely under permit-to-work systems, electrical isolation, Lockout/Tagout, and site RAMS requirements.
- Operate, maintain, and routinely test critical site systems, including fire detection, fire pumps, deluge systems, purified water systems, and critical process equipment.
- Support commissioning, qualification, and small-scale engineering projects.
- Ensure maintenance, calibration, and inspection activities meet GMP standards and are fully documented.
- Work with contractors and service providers to ensure work is completed safely, compliantly, and to site standards.
- Work across engineering, operations, quality, and external contractor teams.
- An Inspection and Testing qualification, such as City & Guilds 2391 or equivalent.
- PLC fault-finding experience, with Siemens experience preferred.
- Experience in pharmaceutical, COMAH, ATEX, or highly regulated manufacturing environments.
- Confined Space Entry and Standby Person training.
Dr. Reddy's Laboratories focuses on affordable generic medicines and pharmaceutical ingredients. Its products include generic drugs and active pharmaceutical ingredients (APIs) produced in-house and distributed worldwide. The company grew from a Hyderabad-based startup in 1984, becoming the first Indian firm to export APIs to Europe in 1986 and to enter the U.S. market in the early 1990s, culminating in a 2001 NYSE listing that underscored its global standards. Today, the group operates in over 150 countries, supported by ongoing research and development to create new and improved medications. The core goal is to improve global health by providing high-quality, affordable healthcare solutions at scale.
Company Size
10,001+
Company Stage
IPO
Headquarters
Hyderabad, India
Founded
1984
Get referred to Dr. Reddy's Laboratories
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 FY27 revenue reached ₹80,705 million on July 22, 2026, despite semaglutide disruptions.
- Bosutinib targets Bosulif's $253.8 million U.S. sales base with first-file exclusivity.
- June 15, 2026 HiveMinds deal expands OTC and nutrition e-commerce monetization.
What critics are saying
- July 22, 2026 semaglutide batches triggered ₹2.4 billion provisions and a 69% profit drop.
- FDA issued four observations at Bachupally on August 14, 2026.
- FDA issued three observations at Srikakulam on July 29, 2026.
What makes Dr. Reddy's Laboratories unique
- Dr. Reddy’s pairs U.S. regulatory execution with MSN and global supply-network partnerships.
- On June 13, 2026, it launched first-to-market generic bosutinib with 180-day exclusivity.
- It still holds a broad emerging-markets and India franchise across 150 countries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Parental Leave
Relocation Assistance
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 12%1 year growth
↑ 12%2 year growth
↑ 12%The Law Offices of Frank R. Cruz has announced an investigation into Dr. Reddy's Laboratories concerning possible violations of federal securities laws. The investigation follows Dr. Reddy's first quarter fiscal 2027 earnings announcement on 22 July 2026. The company reported earnings per share of only $0.06, impacted by a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli stated the quarter's EBITDA margin was adversely affected by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs. Following the announcement, Dr. Reddy's stock price fell $1.18, or 9.4%, closing at $11.38 on 22 July 2026.
Dr. Reddy's Laboratories has launched generic versions of Bridion (sugammadex injection) in the United States on the first day of generic availability. The company introduced 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex injection is used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and paediatric patients aged 2 years and older undergoing surgery. The product is manufactured through Dr. Reddy's global supply network. According to IQVIA National Sales Perspectives data, the branded Bridion had US sales of approximately $1.6 billion for the 12-month period ended May 2026. Dr. Reddy's described the launch as part of its strategy to expand its hospital portfolio and improve patient access to affordable medicines.
Dr Reddy's Laboratories reported Q1 2027 revenue of INR8,071 crores (USD853 million), declining 5.6% year-over-year but growing 7.4% sequentially. The company's EBITDA margin stood at 12.5%, impacted by semaglutide API-related challenges; excluding this impact, the margin was 15.4%. North America revenue fell 41% year-over-year to $236 million but grew 19% sequentially. Emerging markets revenue increased 31% year-over-year to INR1,833 crores, whilst India revenue rose 17% to INR1,780 crores. The company maintained a net cash surplus of INR3,057 crores (USD323 million). Dr Reddy's launched several complex generic products, including Bosutinib in the United States and semaglutide in Canada and India.
Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer. ET Online Last Updated: Jul 17, 2026, 02:18:00 PM IST India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India. Novo Nordisk said on Friday that India's drug regulator has approved its blockbuster obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive form of fatty liver disease. The Central Drugs Standard Control Organisation (CDSCO) has approved Wegovy's 2.4 mg semaglutide injection for the treatment of MASH, the Danish drugmaker said. The approval follows a recommendation by the CDSCO's Subject Expert Committee (SEC) on Endocrinology and Metabolism, which had cleared the drug for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, at stages F2 to F3, during a meeting held on April 23, 2026. You May Like MASH, formerly known as nonalcoholic steatohepatitis (NASH), is caused by a buildup of fat in the liver that can lead to inflammation and liver damage. The condition is part of a broader spectrum of fatty liver disease and can progress to more severe complications, including cirrhosis and liver failure, if left untreated. Novo Nordisk said about two in three people in India have fatty liver disease, underscoring the country's large potential patient population. The company described it as a silent disease, noting that people often do not experience symptoms until it has progressed to an advanced stage. Wegovy contains the active ingredient semaglutide and was first approved in India on April 20, 2022, for chronic weight management, before Friday's expanded approval for the liver condition. The drug is already approved in multiple markets for weight management, and had previously secured MASH approvals abroad, including in the US in August 2025, where it became the first and only GLP-1 receptor agonist approved to treat adults with MASH with moderate to advanced liver scarring, excluding cirrhosis, and in Canada, where it received conditional marketing authorization as the first and only treatment for adults with non-cirrhotic MASH. The US approval was based on Part 1 of the ESSENCE trial, which showed a statistically significant improvement in liver fibrosis with no worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of fibrosis, compared with placebo. Novo has been vying for a share of India's fast-growing obesity-drug market against Eli Lilly's Mounjaro and lower-cost generic semaglutide products launched by local drugmakers such as Dr Reddy's and Sun Pharma. The company sold about 76,000 units of Wegovy in India in the first six months of 2026, according to data from market researcher Pharmarack. Read More News on
HiveMinds secures integrated digital mandate for Dr. Reddy's select OTC and butrition brands. June 15, 2026 HiveMinds, a part of the Madison Group, has secured the integrated digital marketing mandate for Dr. Reddy's Laboratories (Dr. Reddy's), a global pharmaceutical company. The mandate is aimed at strengthening digital presence, accelerating e-commerce growth, and enhancing consumer engagement across channels for Dr. Reddy's select over-the-counter (OTC) and nutrition brands. As part of the mandate, HiveMinds will provide an integrated digital strategy, including full-funnel e-commerce management across channels and creative services to drive impactful consumer experiences. The mandate will be managed by HiveMinds Mumbai team, with a focus on optimising the consumer journey, improving performance metrics, and delivering data-driven, high-impact creative solutions. Deepti Bhaduria, CEO, HiveMinds said, "Health and wellness is a very interesting space for digital today, and Dr. Reddy's has already built strong consumer relevance across categories. We're excited to partner with them at this stage of their growth journey. "With our strength in commerce, creative and experimentation, we believe we can help scale customer acquisition meaningfully and build a strong digital engine for the brand," Bhaduria added.